- Aimedbio and GC cell signs a co-development agreement for a CAR-NK
cell therapy drug
- The contract aims to derive candidates for
CAR-NK drugs using Aimedbio’s 'AMB015' antibodies that bind to cancer-specific
proteins.
- Through this collaboration, Aimedbio hopes to expand their
antibody-based therapeutics development area from ADCs to cell therapy.
Link to full news: http://www.biospectator.com/view/news_view.php?varAtcId=16852